We then tested the ability of the established DL technique to discriminate CJD patients from non-CJD patients based on detection levels of the key CSF biomarkers 14–3-3, a-syn, amyloid beta (Aβ), t-tau, and p-tau. Here, MAPT is linked to Creutzfeldt Jacob disease.